(NYSE: BHVN) Biohaven's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.81%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.82%.
Biohaven's earnings in 2026 is -$647,677,000.On average, 20 Wall Street analysts forecast BHVN's earnings for 2026 to be -$461,303,817, with the lowest BHVN earnings forecast at -$486,914,242, and the highest BHVN earnings forecast at -$409,450,612. On average, 20 Wall Street analysts forecast BHVN's earnings for 2027 to be -$356,061,685, with the lowest BHVN earnings forecast at -$473,634,762, and the highest BHVN earnings forecast at -$248,199,792.
In 2028, BHVN is forecast to generate -$298,788,285 in earnings, with the lowest earnings forecast at -$467,732,772 and the highest earnings forecast at -$67,978,287.